Loading...
Market
Story
FDA Grants Accelerated Approval to EPKINLY®, First Bispecific Antibody for Relapsed/Refractory Follicular Lymphoma
Jun 26, 2024, 11:38 PM
The U.S. Food and Drug Administration (FDA) has granted accelerated approval to Epcoritamab, marketed as EPKINLY®, for the treatment of relapsed or refractory follicular lymphoma (R/R FL). This approval marks the second for EPKINLY® and makes it the first bispecific antibody approved for both R/R FL and relapsed or refractory diffuse large B-cell lymphoma (R/R DLBCL) in the U.S. The drug is developed by AbbVie and Genmab, trading under the stock symbols $ABBV and $GMAB respectively. The approval has been highlighted in the #lymsm and #oncology communities.
View original story
Similar markets
Stock price increases by over 50% • 33%
Stock price remains within 20% of current value • 34%
Stock price decreases by over 20% • 33%
Yes • 50%
No • 50%
Less than 5% • 25%
5% to 6% • 25%
6% to 7% • 25%
More than 7% • 25%
Outperform • 25%
Underperform • 25%
Match performance • 25%
Significantly underperform • 25%
Below $150 • 25%
$150 - $175 • 25%
$175 - $200 • 25%
Above $200 • 25%
Increase by more than 5% • 25%
Increase by up to 5% • 25%
Decrease by up to 5% • 25%
Decrease by more than 5% • 25%
Below $30 • 25%
$30-$40 • 25%
$40-$50 • 25%
Above $50 • 25%
Below $50 • 25%
$50 to $75 • 25%
$75 to $100 • 25%
Above $100 • 25%
Below $50 • 25%
$50-$74.99 • 25%
$75-$99.99 • 25%
$100 or higher • 25%
Less than 10% • 25%
10% to 20% • 25%
20% to 30% • 25%
More than 30% • 25%